← Leaderboards
William Nathaniel Brennen
Johns Hopkins University
$3,292,142
Attributed
$3,292,142
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,292,142 · 2
By mechanism
R01$3,292,142 · 2
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Elizabeth Marion Jaffee$29,780,612
- William B Isaacs$27,729,214
- Angelo Michael De Marzo$8,441,808
- Jonathan Epstein$978,862
Others in their field
Other Emerging Leaders on “Resistance Mechanism”
- Ionut Bebu · George Washington University$14,057,850
- Barbara Halina Braffett · George Washington University$14,057,850
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
- Timothy M Willson · University Of Cape Town$12,760,250
- Crystal Mackall · Children'S Hosp Of Philadelphia$9,609,767
- Thomas Dick · Rbhs-New Jersey Medical School$9,402,832
Research focus
Resistance MechanismResistanceOralMalignant Neoplasm Of ProstatePre-Clinical ModelProstate Cancer TherapyHormonalFutureInnovationIn VivoPharmaceutical PreparationsPhenotypeCombatBiological ModelsAndrogen ReceptorDrug KineticsCancer PatientFda ApprovedAbirateroneCastrationIn VitroCellsPatient Derived Xenograft ModelResponse
Grant awards (7)
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer$582,108
R01 · FY2025 · CA · contact PI
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression$415,155
R01 · FY2025 · CA · contact PI
Molecular features promoting sensitivity to LSD1i in castration-resistant prostate cancer$606,756
R01 · FY2024 · CA · contact PI
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression$394,398
R01 · FY2024 · CA · contact PI
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression$406,852
R01 · FY2023 · CA · contact PI
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression$415,155
R01 · FY2022 · CA · contact PI
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression$471,718
R01 · FY2021 · CA · contact PI